Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines

View ORCID ProfileLeticia Monin-Aldama, View ORCID ProfileAdam G. Laing, View ORCID ProfileMiguel Muñoz-Ruiz, View ORCID ProfileDuncan R McKenzie, View ORCID ProfileIrene del Molino del Barrio, View ORCID ProfileThanussuyah Alaguthurai, View ORCID ProfileClara Domingo-Vila, View ORCID ProfileThomas S. Hayday, Carl Graham, View ORCID ProfileJeffrey Seow, Sultan Abdul-Jawad, View ORCID ProfileShraddha Kamdar, Elizabeth Harvey-Jones, Rosalind Graham, Jack Cooper, Muhammad Khan, View ORCID ProfileJennifer Vidler, Helen Kakkassery, Sinha Shubhankar, View ORCID ProfileRichard Davis, Liane Dupont, View ORCID ProfileIsaac Francos Quijorna, Puay Lee, Josephine Eum, Maria Conde Poole, View ORCID ProfileMagdalene Joseph, Daniel Davies, View ORCID ProfileYin Wu, View ORCID ProfileAna Montes, Mark Harries, View ORCID ProfileAnne Rigg, View ORCID ProfileJames Spicer, View ORCID ProfileMichael H Malim, View ORCID ProfilePaul Fields, View ORCID ProfilePiers Patten, View ORCID ProfileFrancesca Di Rosa, View ORCID ProfileSophie Papa, View ORCID ProfileTim Tree, View ORCID ProfileKatie Doores, View ORCID ProfileAdrian C. Hayday, View ORCID ProfileSheeba Irshad
doi: https://doi.org/10.1101/2021.03.17.21253131
Leticia Monin-Aldama
1The Francis Crick Institute, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leticia Monin-Aldama
Adam G. Laing
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adam G. Laing
Miguel Muñoz-Ruiz
1The Francis Crick Institute, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Miguel Muñoz-Ruiz
Duncan R McKenzie
1The Francis Crick Institute, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Duncan R McKenzie
Irene del Molino del Barrio
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
3UCL Cancer Institute, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Irene del Molino del Barrio
Thanussuyah Alaguthurai
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
5Breast Cancer Now Research Unit, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thanussuyah Alaguthurai
Clara Domingo-Vila
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Clara Domingo-Vila
Thomas S. Hayday
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas S. Hayday
Carl Graham
6Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Seow
6Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeffrey Seow
Sultan Abdul-Jawad
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shraddha Kamdar
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shraddha Kamdar
Elizabeth Harvey-Jones
5Breast Cancer Now Research Unit, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosalind Graham
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Cooper
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammad Khan
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Vidler
8Department of Haematological Medicine, King’s College Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer Vidler
Helen Kakkassery
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sinha Shubhankar
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Davis
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Davis
Liane Dupont
5Breast Cancer Now Research Unit, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isaac Francos Quijorna
9Regeneration Group, Wolfson Centre for Age-Related Diseases, IoPPN, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Isaac Francos Quijorna
Puay Lee
1The Francis Crick Institute, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josephine Eum
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Conde Poole
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalene Joseph
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Magdalene Joseph
Daniel Davies
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yin Wu
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yin Wu
Ana Montes
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana Montes
Mark Harries
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Rigg
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne Rigg
James Spicer
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James Spicer
Michael H Malim
6Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael H Malim
Paul Fields
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
8Department of Haematological Medicine, King’s College Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Fields
Piers Patten
1The Francis Crick Institute, London, UK
8Department of Haematological Medicine, King’s College Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Piers Patten
Francesca Di Rosa
10Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francesca Di Rosa
Sophie Papa
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sophie Papa
Tim Tree
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tim Tree
Katie Doores
6Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katie Doores
Adrian C. Hayday
1The Francis Crick Institute, London, UK
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adrian C. Hayday
  • For correspondence: adrian.hayday@kcl.ac.uk sheeba.irshad@kcl.ac.uk
Sheeba Irshad
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
5Breast Cancer Now Research Unit, King’s College London, London, UK
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
11Cancer Research UK (CRUK) Clinician Scientist, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sheeba Irshad
  • For correspondence: adrian.hayday@kcl.ac.uk sheeba.irshad@kcl.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The efficacy and safety profile of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in immunocompromised patient populations. Patients with a known cancer diagnosis were hitherto excluded from trials of the vaccines currently in clinical use.

Methods This study presents data on the safety and immune efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine in 54 healthy controls and 151 mostly elderly patients with solid and haematological malignancies, respectively, and compares results for patients who were boosted with BNT162b2 at 3 weeks versus those who were not. Immune efficacy was measured as antibody seroconversion, T cell responses, and neutralisation of SARS-CoV-2 Wuhan strain and of a variant of concern (VOC) (B.1.1.7). We also collected safety data for the BNT162b2 vaccine up to 5 weeks following first dose.

Findings The vaccine was largely well tolerated. However, in contrast to its very high performance in healthy controls (>90% efficacious), immune efficacy of a single inoculum in solid cancer patients was strikingly low (below 40%) and very low in haematological cancer patients (below 15%). Of note, efficacy in solid cancer patients was greatly and rapidly increased by boosting at 21-days (95% within 2 weeks of boost). Too few haematological cancer patients were boosted for clear conclusions to be drawn.

Conclusions Delayed boosting potentially leaves most solid and haematological cancer patients wholly or partially unprotected, with implications for their own health; their environment and the evolution of VOC strains. Prompt boosting of solid cancer patients quickly overcomes the poor efficacy of the primary inoculum in solid cancer patients.

Evidence before this study Some cancer patients have been shown to exhibit sustained immune dysregulation, inefficient seroconversion and prolonged viral shedding as a consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Consequently, their exclusion and, in particular, the exclusion of patients receiving systemic anti-cancer therapies, from the registry trials of the 5 approved COVID-19 vaccines raises questions about the efficacy and safety of SARS-CoV-2 vaccination in this patient population. In addition, whilst the change in the UK’s dosing interval to 12-weeks aimed to maximise population coverage, it is unclear whether this strategy is appropriate for cancer patients and those on systemic anti-cancer therapies.

Added value of this study We report that the RNA-based SARS-CoV-2 BNT162b2 vaccine administered in cancer patients was well tolerated, and we provide first insights into both antibody and T cell responses to the vaccine in an immunocompromised patient population.

Implications of all the available evidence In cancer patients, one dose of 30ug of BNT162b2 yields poor vaccine efficacy, as measured by seroconversion rates, viral neutralisation capacity and T cell responses, at 3- and 5-weeks following the first inoculum. Patients with solid cancers exhibited a significantly greater response following a booster at 21-days. These data support prioritisation of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine. Given the globally poor responses to vaccination in patients with haematological cancers, post-vaccination serological testing, creation of herd immunity around these patients using a strategy of ‘ring vaccination’, and careful follow-up should be prioritised.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

IRAS ID: 282337, REC ID: 20/HRA/2031

Funding Statement

We thank patients and blood donors consenting in this study and the medical and research teams at Guys and St. Thomas Trust (GSTT) hospitals. We thank members of the GSTT and Kings College Hospital (KCH) trial teams who contributed to patient recruitment for the SOAP study at GSTT and KCH hospitals; and clinical colleagues at GSTT, KCH, and PRUH for assisting with patient identification and sample collection. The SOAP study (IRAS 282337) is sponsored by Kings College London and GSTT Foundation NHS Trust. It is funded from grants from the KCL Charity funds to S.I. (PS10822), Cancer Research UK to S.I. (C56773 / A24869), program grants from Breast Cancer Now including S.I. at Kings College London and to the Breast Cancer Now Toby Robins Research Center at the Institute of Cancer Research, London. This work was also supported by the Wellcome Trust Investigator Award to A.C.H. (106292/Z/14/Z), the Rosetrees and John Black Charitable Foundation award to A.C.H ( 11130 ), the Cancer Research UK Cancer Immunotherapy Accelerator and a UK COVID-Immunology-Consortium (CIC) grant to AH (C33499/A20265); the Kings Together Rapid COVID-19 Call awards to K.J.D and M.H.M and A.C.H; the Foundation Dormeur, Vaduz for funding equipment to K.J.D; the Huo Family Foundation Award to M.H.M and K.J.D; the Cancer Research Institute Irvington Fellowship (D.R.M); the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (C.G., MR/N013700/1); and the Francis Crick Institute (A.C.H.), which receives core funding from Cancer Research UK (FC001093), the MRC (FC001093) and the Wellcome Trust (FC001093).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The SOAP study was sponsored by Kings College London and GSTT Foundation NHS Trust. The study was reviewed and ethical approval given by the London Bridge NHS Research Ethics Committee (IRAS ID: 282337 REC ID: 20/HRA/2031

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Upon request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 17, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
Leticia Monin-Aldama, Adam G. Laing, Miguel Muñoz-Ruiz, Duncan R McKenzie, Irene del Molino del Barrio, Thanussuyah Alaguthurai, Clara Domingo-Vila, Thomas S. Hayday, Carl Graham, Jeffrey Seow, Sultan Abdul-Jawad, Shraddha Kamdar, Elizabeth Harvey-Jones, Rosalind Graham, Jack Cooper, Muhammad Khan, Jennifer Vidler, Helen Kakkassery, Sinha Shubhankar, Richard Davis, Liane Dupont, Isaac Francos Quijorna, Puay Lee, Josephine Eum, Maria Conde Poole, Magdalene Joseph, Daniel Davies, Yin Wu, Ana Montes, Mark Harries, Anne Rigg, James Spicer, Michael H Malim, Paul Fields, Piers Patten, Francesca Di Rosa, Sophie Papa, Tim Tree, Katie Doores, Adrian C. Hayday, Sheeba Irshad
medRxiv 2021.03.17.21253131; doi: https://doi.org/10.1101/2021.03.17.21253131
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
Leticia Monin-Aldama, Adam G. Laing, Miguel Muñoz-Ruiz, Duncan R McKenzie, Irene del Molino del Barrio, Thanussuyah Alaguthurai, Clara Domingo-Vila, Thomas S. Hayday, Carl Graham, Jeffrey Seow, Sultan Abdul-Jawad, Shraddha Kamdar, Elizabeth Harvey-Jones, Rosalind Graham, Jack Cooper, Muhammad Khan, Jennifer Vidler, Helen Kakkassery, Sinha Shubhankar, Richard Davis, Liane Dupont, Isaac Francos Quijorna, Puay Lee, Josephine Eum, Maria Conde Poole, Magdalene Joseph, Daniel Davies, Yin Wu, Ana Montes, Mark Harries, Anne Rigg, James Spicer, Michael H Malim, Paul Fields, Piers Patten, Francesca Di Rosa, Sophie Papa, Tim Tree, Katie Doores, Adrian C. Hayday, Sheeba Irshad
medRxiv 2021.03.17.21253131; doi: https://doi.org/10.1101/2021.03.17.21253131

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (195)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5674)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (863)
  • Geriatric Medicine (88)
  • Health Economics (230)
  • Health Informatics (761)
  • Health Policy (390)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6467)
  • Intensive Care and Critical Care Medicine (390)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (846)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (162)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (113)
  • Psychiatry and Clinical Psychology (963)
  • Public and Global Health (2224)
  • Radiology and Imaging (376)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)